Clinical Efficacy of Silodosin in Patients with Severe Lower Urinary Tract Symptoms Related to Benign Prostatic Obstruction: A Pooled Analysis of Phase 3 and 4 Trials

Massimiliano Creta, Jean Nicolas Cornu, Claus G. Roehrborn, Enrico Finazzi Agrò, Francesco Montorsi, Nicola Longo, Vittorio Imperatore, Marco De Sio, Davide Arcaniolo, Vincenzo Mirone, Ferdinando Fusco

Research output: Contribution to journalArticlepeer-review

Abstract

We performed a post hoc analysis of data from phase 3 and 4 studies to evaluate the efficacy of silodosin 8 mg in patients with severe lower urinary tract symptoms (LUTS) related to benign prostatic obstruction (BPO). The presence of two or more of the following criteria was adopted to define severity: total International Prostate Symptom Score (IPSS) 20–35, quality of life (QoL) score 5–6, maximum urinary flow <5 ml/s or postvoid residual volume ≥100 ml, and prostate volume ≥50 ml. Mean improvements in total (8.1 vs 4.7), storage (3.1 vs 2.0), voiding (5.0 vs 2.7), and QoL (1.3 vs 0.7) IPSS scores were significantly greater for patients receiving silodosin compared to placebo (all p < 0.0001). Mean improvements in total, storage, voiding, and QoL IPSS scores were similar for the severe and not severe LUTS cohorts. In conclusion, silodosin significantly improves symptoms and QoL in all LUTS/BPO patients, including those with severe symptoms. Patient summary: Silodosin improves symptoms and quality of life for patients with severe lower urinary tract symptoms related to benign prostatic obstruction.

Original languageEnglish (US)
Pages (from-to)440-443
Number of pages4
JournalEuropean Urology Focus
Volume7
Issue number2
DOIs
StatePublished - Mar 2021

Keywords

  • Benign prostatic obstruction
  • Lower urinary tract symptoms
  • Silodosin

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'Clinical Efficacy of Silodosin in Patients with Severe Lower Urinary Tract Symptoms Related to Benign Prostatic Obstruction: A Pooled Analysis of Phase 3 and 4 Trials'. Together they form a unique fingerprint.

Cite this